NEW YORK (EFE).— The pharmaceutical company Moderna announced yesterday that it began the last phase of clinical testing of four vaccines once morest latent infections, including chickenpox and herpes.
The four biologics once morest latent infections are for diseases caused by pathogens of the herpesvirus family: cytomegalovirus (the infection that causes the most birth defects in the United States), Epstein-Barr (the main cause of acute infectious mononucleosis), herpes simplex and varicella-zoster (responsible for chickenpox).
Additionally, the company is in the final phase of developing a vaccine once morest the norovirus, which causes outbreaks of gastroenteritis around the world and regarding 200,000 deaths a year.
Moderna took advantage of the commemoration of its fifth Vaccine Day to announce a new generation vaccine once morest Covid-19, effective for the BA.4 and BA.5 omicron variants and the original strains.
This new generation allowed the development of a vaccine candidate once morest flu and Covid-19 for people over 50 years of age.
“Covid-19 remains a high-burden disease and although hospitalizations remain high relative to human respiratory syncytial virus (RSV) and influenza, the risks of long-term Covid are beginning to be better understood,” the company said. it’s a statement.
Regarding RSV, which mainly affects children and can have long-term consequences, Moderna pointed out that its vaccine candidate is in phase 2/3 of clinical trials, in which 37,000 people over 60 years of age in 22 countries participate.
Moderna hopes the vaccine will be approved by US authorities this year.
At this time, Moderna’s only commercial vaccine is that for Covid-19, which uses the messenger RNA technique, the basis of all the vaccines that the company is developing.
Related news
#create #vaccine #chickenpox
2024-04-04 15:06:04
